Dr. Rüdiger Herrmann focuses his practice on key transactions in the biotechnology and pharmaceutical sectors. He has a wealth of experience advising national and international clients on mergers and acquisitions, licensing agreements, initial public offerings, intellectual property matters and private equity/venture capital transactions. He has a particularly strong background in dealing with life science matters in the US, Europe, China and Taiwan.
Rüdiger is an international speaker on biotechnology, pharmaceuticals, private equity and M&A topics, having lectured at Bio International, Bio Europe, Bio Equity, and the Venture Capital forum in London, among other conferences.
Advised uniQure on an exclusive strategic collaboration with Bristol-Myers Squibb*
Advised 4SC on a licensing and development partnership for its lead compound with Menarini*
Advised 4SC on a licensing and development partnership for cancer compound with Link Health*
Advised a Dutch biotech company on a commercialization agreement for gene therapy product and a co-development agreement with an Italian pharma company*
Represented Canada-based biotech company Resverlogix in a license and equity investment transaction with a Chinese public listed company Shenzhen Hepalink Pharmaceutical Co. for Resverlogix’s RVX-208 program*
Advised a leading German medical and pharmaceutical device company on its joint venture project in the Middle East and Russia*
Advised Lohmann Animal Health GmbH on its joint venture and license transaction with China Wuhan Sunhy Biotech Co., Ltd*
Represented PAION AG in its cross-border licensing transaction with China Yichang Humanwell Co., Ltd*
Advised Lohmann Animal Health GmbH on the establishment of a wholly Foreign Owned Enterprise (WFOE) in Shanghai, China*